EQS-News: Sartorius Supervisory Board extends appointment of board member Alexandra Gatzemeyer
|
EQS-News: SARTORIUS AG
/ Key word(s): Personnel
At today’s meeting, the Supervisory Board of Sartorius AG resolved to extend the appointment of Dr. Alexandra Gatzemeyer as a member of the Executive Board by a five-year period to April 30, 2031. Gatzemeyer, who holds a Ph.D. in chemistry and pharmacology, has been with Sartorius since 2004 and was appointed to the Executive Board in March 2023. As a board member, she is responsible for the Lab Products & Services Division.
A profile of Sartorius Sartorius is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. More than 13,500 employees work for customers around the globe. Visit our Newsroom or follow us on LinkedIn. Contact Petra Kirchhoff Head of Corporate Communications & Investor Relations +49 551 308 1686 petra.kirchhoff@sartorius.com Additional features: File: Image_Alexandra Gatzemeyer_Sartorius File: 20250502_Media Release_SAG_Extension of appointment of Alexandra Gatzemeyer_EN
02.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SARTORIUS AG |
| Otto-Brenner-Straße 20 | |
| 37079 Göttingen | |
| Germany | |
| Phone: | +49.(0)551-308.0 |
| Fax: | +49.(0)551-308.3289 |
| E-mail: | info@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | DE0007165631, DE0007165607 |
| WKN: | 716563, 716560 |
| Indices: | DAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2127076 |
| End of News | EQS News Service |
|
|
2127076 02.05.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 1.826,97 | 2.335,66 | 3.449,22 | 4.174,70 | 3.395,70 | 3.380,70 | 3.615,00 | |
| EBITDA1,2 | 495,80 | 636,70 | 1.134,26 | 1.410,40 | 962,70 | 945,30 | 1.070,00 | |
| EBITDA-Margin3 | 27,14 | 27,26 | 32,89 | 33,78 | 28,35 | 27,96 | 29,60 | |
| EBIT1,4 | 335,66 | 456,11 | 903,16 | 1.064,80 | 503,90 | 530,00 | 0,00 | |
| EBIT-Margin5 | 18,37 | 19,53 | 26,18 | 25,51 | 14,84 | 15,68 | 0,00 | |
| Net Profit (Loss)1 | 218,74 | 299,56 | 426,98 | 913,10 | 290,60 | 137,40 | 325,00 | |
| Net-Margin6 | 11,97 | 12,83 | 12,38 | 21,87 | 8,56 | 4,06 | 8,99 | |
| Cashflow1,7 | 377,19 | 511,53 | 865,81 | 734,20 | 853,60 | 976,00 | 875,00 | |
| Earnings per share8 | 3,07 | 4,38 | 8,09 | 9,58 | 4,95 | 5,30 | 4,30 | |
| Dividend per share8 | 0,36 | 0,71 | 1,26 | 1,44 | 0,74 | 0,74 | 1,24 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Sartorius VZ | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 716563 | DE0007165631 | AG | 16.862,98 Mio € | 10.07.1990 | Halten | 9F3FHV2Q+JW |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 47,85 | 39,19 | 1,22 | 58,31 | 7,28 | 19,45 | 4,99 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,74 | 0,74 | 1,24 | 0,49% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 27.03.2025 | 16.04.2025 | 22.07.2025 | 16.10.2025 | 17.02.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +12,98% | +17,55% | +17,84% | +19,57% | +4.223,96% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
